Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2020 - 12 - 21 tags : Approval save search
Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital MarketTrading on Nasdaq Capital Market is expected to begin on December 23, 2020
Published: 2020-12-21 (Crawled : 00:00) - biospace.com/
ITRM | $1.45 -0.69% -0.69% 57K
|
Health Technology
|
| O: -0.11%
H: 11.86%
C: 9.28%
approval nasdaq
Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations
Published: 2020-12-21 (Crawled : 00:00) - biospace.com/
VRTX | $393.51 0.1% 0.1% 950K
|
Health Technology
|
| O: -1.56%
H: 1.1%
C: 0.66%
fda approval fda approval rare
Eaton Vance Floating-Rate Income Plus Fund Announces Board Approval of New Investment Advisory Agreement
Published: 2020-12-21 (Crawled : 22:07) - prnewswire.com
MS | News 0 d | $90.26 0.2% 0.0% 6.7M
|
Finance
|
| O: 0.62%
H: 0.0%
C: -2.36%
approval
Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
Published: 2020-12-21 (Crawled : 22:03) - globenewswire.com
ITRM | $1.45 -0.69% -0.69% 57K
|
Health Technology
|
| O: 5.42%
H: 4.85%
C: 0.97%
approval therapeutics nasdaq
Taysha Gene Therapies Announces Queen’s University’s Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis
Published: 2020-12-21 (Crawled : 15:00) - biospace.com/
TSHA | $2.4 -2.04% -2.08% 2M
|
Health Technology
|
| O: -0.94%
H: 2.89%
C: -0.05%
approval therapy gene therapies trial phase 3 phase 1 phase 2 gene therapy tsha-102
Strategic combination plan receives all key regulatory approvals
Published: 2020-12-21 (Crawled : 14:00) - globenewswire.com
CVE | $20.66 -0.19% -0.77% 9.4M
|
Energy Minerals
|
| O: -6.41%
H: 4.41%
C: 3.24%
approval
Legend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2020-12-21 (Crawled : 14:00) - biospace.com/
LEGN | $47.16 -3.42% -3.54% 820K
|
Health Technology
|
| O: -2.15%
H: 2.64%
C: -0.7%
fda approval biotech license therapy car-t submission cel
CVR Energy Announces Full Board Approval for Wynnewood Renewable Diesel Unit Project
Published: 2020-12-21 (Crawled : 13:03) - globenewswire.com
CVI | $32.55 -2.57% 0.15% 620K
|
Energy Minerals
|
| O: -4.65%
H: 2.12%
C: 0.14%
approval renewable energy
Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
Published: 2020-12-21 (Crawled : 12:03) - globenewswire.com
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 2.43%
H: 3.76%
C: -7.52%
approval treatment libmeldy
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
Published: 2020-12-21 (Crawled : 00:12) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 2.67%
H: 1.3%
C: -3.25%
fda approval fda approval therapy
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.